The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,518.00
Bid: 12,516.00
Ask: 12,520.00
Change: 114.00 (0.92%)
Spread: 4.00 (0.032%)
Open: 12,500.00
High: 12,518.00
Low: 12,444.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: NY Seen Up As Fed Decision Week Gets Underway

Mon, 14th Sep 2015 11:12

LONDON (Alliance News) - UK stocks were mostly flat midday Monday, while Wall Street was called for a slightly positive open, with investors focusing on the Federal Reserve's two-day policy meeting concluding on Thursday as expectations for a US interest rate hike remained finely balanced.

The FTSE 100 index traded up 0.2% at 6,131.61, the FTSE 250 was flat at 16,974.03, and the AIM All-Share was flat at 733.59. In Europe, the CAC 40 index in Paris was up 0.3% and the DAX 30 in Frankfurt was up 0.4%.

US stock futures pointed to a higher open, with the Dow Jones Industrial Average seen up 0.2%, and the S&P 500 and the Nasdaq 100 both pointed up 0.3%. Wall Street closed higher Friday, with the Dow up 0.6% and the S&P 500 and the Nasdaq Composite both up 0.5%.

The Federal Open Market Committee will hold a crucial two-day monetary policy later this week, following which some market commentators believe it will announce the first US rate hike since 2006. But expectations are finely balanced going into the week, and the event is likely to heighten uncertainty in the market.

IG market analyst Joshua Mahony said a rate hike on Thursday is unlikely "given the sheer size of moving parts including a mid-selloff stock market, a waning Chinese economy, and multi-year lows in oil with an associated impact upon [US] inflation, jobs and [economic] growth."

But the analyst noted that, with the markets factoring in a 28% chance of some sort of rate hike, there is enough backing to induce major volatility come Thursday.

"The question is whether a decision not to hike will even be enough to lift global indices out of the current negative mindset that has dominated the past five months," said Mahony.

Most of the negative sentiment in the past months has been caused by concerns about the Chinese economy and the resulting sell off in Asian stock markets. On Monday, the Nikkei 225 in Tokyo closed down 1.6%, while China's major stock indices ended mixed, with the Shanghai Composite down 2.7% and the Hang Seng index in Hong Kong up 0.3%.

There were mixed economic data from the Asian giant on Sunday. Chinese industrial production was up by 6.1% year-on-year in August, according to the country's National Bureau of Statistics. This was marginally better than the 6.0% growth reported in July, but below expectations of 6.4%.

In addition, fixed-asset investment in non-rural areas of the country rose by 10.9% in the first eight months of the year, but this was below expectations of 11.1% growth and slower than the 11.2% increase measured for the first seven months.

However, retail sales in China grew 10.8% year-on-year in August, beating the 10.5% consensus and July reading.

On the London Stock Exchange, ARM Holdings was the best performer in the FTSE 100, up 2.6%.

Accendo Markets head of research Mike van Dulken said that shares in the chip designer were benefiting from some positive reviews released over the weekend of Apple's latest product launches and updates, including to the iPhone and iPad, announced at an event last Wednesday. The California-based tech giant is one of the most important customers for ARM.

Miners were pushing higher in London on Monday despite the continued worries about the Chinese economy, as expectations of further stimulus by Chinese authorities are thought to be again on the table.

Rio Tinto, up 2.2%, BHP Billiton, up 2.0%, Fresnillo, up 1.7%, Randgold Resources, up 1.4%, were among the best blue-chip performers. BHP was upgraded to Buy from Hold by Jefferies.

In the red was Glencore, down 1.7% after the multi-commodities miner said the board of the company behind the Katanga mine in the Democratic Republic of Congo, in which it holds 74%, has confirmed it will suspend copper and cobalt production at the site for 18 months. Glencore had flagged the decision last week when it announced plans to improve its financial condition.

Outside miners, RELX was up 1.0% after being upgraded to Outperform from Underperform by Exane BNP.

AstraZeneca also benefited from an broker upgrade, rising 1.3% as Deutsche Bank raised its recommendation on the stock to Buy from Hold. The bank said it was confident the company will be able to return to strong growth, with analyst Richard Parkes saying this will be driven by execution on its strategy for its growth platforms - diabetes, respiratory, Japan, emerging markets, and heart drug Brilinta - and delivery on its significantly improved pipeline.

In the FTSE 250, fund managers Henderson Group, up 2.6%, and Man Group, up 1.6%, were were in favour after Exane BNP initiated them both at Outperform.

In AIM, Motive Television was up 30%. The company said it plans to make its TabletTV product available on Apple's recently announced new Apple TV platform. TabletTV allows users to watch and record free-over-the air television without a contract or subscription. Motive Television is a registered Apple developer.

Meanwhile, HaiKe Chemical Group was down 40%. The China-based specialty chemicals company said its first half trading was in line with its expectations but said it has taken a hit so far in the second six months from the turbulence in the Chinese economy. The group said it is "at risk" of failing to achieve a full-year profit and said it recorded losses in both July and August due to the tough economic conditions.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more
9 Nov 2023 07:18

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

Read more
3 Nov 2023 17:06

AstraZeneca plans next phase of trial on kidney drug combination data

(Alliance News) - AstraZeneca PLC on Friday touted results from a Phase IIb trial, which showed that a zibotentan and dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria.

Read more
3 Nov 2023 11:34

AstraZeneca's Lokelma lets kidney disease patients maintain therapy

(Alliance News) - AstraZeneca PLC on Thursday celebrated results from an observational study, which showed that treating hyperkalaemia with the potassium binder, Lokelma, allows chronic kidney disease and heart failure patients to maintain RAASi therapy.

Read more
2 Nov 2023 15:57

UK earnings, trading statements calendar - next 7 days

Friday 3 November 
no events scheduled 
Monday 6 November 
Kingspan Group PLCTrading Statement
Kosmos Energy LtdQ3 Results
Ryanair Holdings PLCHalf Year Results
Tuesday 7 November 
Associated British Foods PLCFull Year Results
Beazley PLCQ3 Results
Direct Line Insurance Group PLCTrading Statement
dotdigital Group PLCFull Year Results
IWG PLCQ3 Results
Persimmon PLCTrading Statement
RS Group PLCHalf Year Results
Vaalco Energy IncQ3 Results
Watches of Switzerland Group PLCTrading Statement
Wednesday 8 November 
Conduit Holdings LtdQ3 Results
ITV PLCTrading Statement
JD Wetherspoon PLCQ1 Results
Marks & Spencer Group PLCHalf Year Results
MaxCyte IncQ3 Results
Secure Trust Bank PLCTrading Statement
Smiths News PLCFull Year Results
Time Out Group PLCFull Year Results
Thursday 9 November 
3i Group PLCHalf Year Results
Apax Global Alpha LtdQ3 Results
AstraZeneca PLCQ3 Results
Auto Trader Group PLCHalf Year Results
B&M European Value Retail SAHalf Year Results
Domino's Pizza Group PLCTrading Statement
Endeavour Mining PLCQ3 Results
Flutter Entertainment PLCTrading Statement
IMI PLCTrading Statement
Indivior PLCQ3 Results
John Wood Group PLCTrading Statement
Lancashire Holdings LtdTrading Statement
National Grid PLCHalf Year Results
Regional REIT LtdTrading Statement
Renewi PLCHalf Year Results
S4 Capital PLCTrading Statement
Tate & Lyle PLCHalf Year Results
Taylor Wimpey PLCTrading Statement
TBC Bank Group PLCQ3 Results
TheWorks.co.uk PLCTrading Statement
Trakm8 Holdings PLCHalf Year Results
Urban Logistics REIT PLCHalf Year Results
Vistry Group PLCTrading Statement
WH Smith PLCFull Year Results
Wincanton PLCHalf Year Results
Wizz Air Holdings PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
1 Nov 2023 08:59

AstraZeneca launches collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Wednesday announced a new collaboration and investment agreement with clinical-stage biotechnology company Cellectis.

Read more
1 Nov 2023 07:33

AstraZeneca invests $220m in French gene-editing group Cellectis

(Sharecast News) - AstraZeneca is to invest in French biopharma group Cellectis to use its gene-editing technologies to develop next-gen therapeutics in areas like oncology, immunology and rare diseases.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.